research use only
Cat.No.S2167
| Related Targets | Adrenergic Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR |
|---|---|
| Other Estrogen/progestogen Receptor Inhibitors | Elacestrant (RAD1901) Dihydrochloride MPP dihydrochloride Cholesterol Endoxifen HCl G15 Chrysin Licochalcone A AZD9496 PHTPP Liquiritigenin |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | |||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | |||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | |||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | |||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 100 mg/mL
(188.44 mM)
Ethanol : 13 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 530.65 | Formula | C30H34N2O3.C2H4O2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 198481-33-3 | -- | Storage of Stock Solutions |
|
|
| Synonyms | TSE-424, WAY-140424 | Smiles | CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O.CC(=O)O | ||
| Targets/IC50/Ki |
estrogen receptor
|
|---|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | p-JAK1 / JAK1 / p-JAK2 / JAK2 / Cleaved caspase-3 / Bcl-2 / Survivin p-STAT3 / STAT3 / p-AKT / p-ERK / Cleaved Caspase-3 |
|
30648776 |
| Growth inhibition assay | Cell viability |
|
30648776 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03475719 | Unknown status | Osteoporosis Postmenopausal |
Huons Co. Ltd. |
January 11 2018 | Phase 1 |
| NCT03005340 | Unknown status | Healthy |
Alvogen Korea |
December 2016 | Phase 1 |
| NCT02729701 | Completed | Breast Cancer |
University of Kansas Medical Center|Pfizer |
May 2016 | Phase 2 |
| NCT01973738 | Unknown status | Selective Estrogen Receptor Modulator |
Toshihiko Kono|Tomidahama Hospital |
January 2012 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.